Exact Sciences (EXAS) Q3 Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/12/2026

1. MIRM
2. SPY
3. META
4. MSFT
5. PLTR
6. JNJ
7. HUM
8. CSCO
9. KTOS
10. NVDA

Go back to Exact Sciences (EXAS) Q3 Revenues Beat

Exact Sciences Announces Third Quarter 2020 Results

October 27, 2020 7:01 AM EDT

MADISON, Wis., Oct. 27, 2020 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $408.4 million for the third quarter ended September 30, 2020, compared to $218.8 million for the same period of 2019.

"The Exact Sciences team delivered a strong quarter and made significant progress towards our vision," said Kevin Conroy, Chairman and CEO. "We're confident in the long-term growth outlook for both Cologuard and Oncotype DX and are excited about our extensive pipeline of liquid biopsy tests. Our team and the depth and breadth of our capabilities position us at the... More